Viking Therapeutics, Inc. (VKTX)의 가격은 얼마입니까?

Viking Therapeutics, Inc. (VKTX)의 가격은 $34.45입니다.

Viking Therapeutics, Inc. (VKTX)의 시가 총액은 무엇입니까?

Viking Therapeutics, Inc. (VKTX)의 시가 총액은 $4.02B입니다.

Viking Therapeutics, Inc. (VKTX) 가격 이력

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

연도	성과
2026 (TTM)	-9.08%
2025	-20.83%
2024	152.59%
2023	215.71%
2022	16.84%
2021	-21.08%
2020	-20.48%
2019	-10.51%
2018	130.53%
2017	246.93%
2016	-60.36%
2015	0.00%

연도

성과

2026 (TTM)

-9.08%

2025

-20.83%

2024

152.59%

2023

215.71%

2022

16.84%

2021

-21.08%

2020

-20.48%

2019

-10.51%

2018

130.53%

2017

246.93%

2016

-60.36%

2015

0.00%

회사	주가	변동률 1년%	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$550.84	42.27%	US
Argenx SE ARGX.US	$1.06K	49.13%	NL
Moderna, Inc. MRNA.US	$147.64	496.99%	US
CSL Limited CSL.AX	$121.62	-12.98%	AU
Lonza Group AG LONN.SW	$764.47	6.25%	CH

회사

주가

변동률 1년%

국가